Unknown

Dataset Information

0

Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.


ABSTRACT: This report describes phase 1 clinical trials performed to assess interactions of oral isavuconazole at the clinically targeted dose (200 mg, administered as isavuconazonium sulfate 372 mg, 3 times a day for 2 days; 200 mg once daily [QD] thereafter) with single oral doses of the cytochrome P450 (CYP) substrates: bupropion hydrochloride (CYP2B6; 100 mg; n = 24), repaglinide (CYP2C8/CYP3A4; 0.5 mg; n = 24), caffeine (CYP1A2; 200 mg; n = 24), dextromethorphan hydrobromide (CYP2D6/CYP3A4; 30 mg; n = 24), and methadone (CYP2B6/CYP2C19/CYP3A4; 10 mg; n = 23). Compared with each drug alone, coadministration with isavuconazole changed the area under the concentration-time curves (AUC? ) and maximum concentrations (Cmax ) as follows: bupropion, AUC? reduced 42%, Cmax reduced 31%; repaglinide, AUC? reduced 8%, Cmax reduced 14%; caffeine, AUC? increased 4%, Cmax reduced 1%; dextromethorphan, AUC? increased 18%, Cmax increased 17%; R-methadone, AUC? reduced 10%, Cmax increased 3%; S-methadone, AUC? reduced 35%, Cmax increased 1%. In all studies, there were no deaths, 1 serious adverse event (dextromethorphan study; perioral numbness, numbness of right arm and leg), and adverse events leading to study discontinuation were rare. Thus, isavuconazole is a mild inducer of CYP2B6 but does not appear to affect CYP1A2-, CYP2C8-, or CYP2D6-mediated metabolism.

SUBMITTER: Yamazaki T 

PROVIDER: S-EPMC5297975 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.

Yamazaki Takao T   Desai Amit A   Goldwater Ronald R   Han David D   Howieson Corrie C   Akhtar Shahzad S   Kowalski Donna D   Lademacher Christopher C   Pearlman Helene H   Rammelsberg Diane D   Townsend Robert R  

Clinical pharmacology in drug development 20160715 1


This report describes phase 1 clinical trials performed to assess interactions of oral isavuconazole at the clinically targeted dose (200 mg, administered as isavuconazonium sulfate 372 mg, 3 times a day for 2 days; 200 mg once daily [QD] thereafter) with single oral doses of the cytochrome P450 (CYP) substrates: bupropion hydrochloride (CYP2B6; 100 mg; n = 24), repaglinide (CYP2C8/CYP3A4; 0.5 mg; n = 24), caffeine (CYP1A2; 200 mg; n = 24), dextromethorphan hydrobromide (CYP2D6/CYP3A4; 30 mg; n  ...[more]

Similar Datasets

| S-EPMC5297980 | biostudies-literature
| S-EPMC4376496 | biostudies-literature
| S-EPMC5599467 | biostudies-literature
| S-EPMC3632951 | biostudies-literature
| S-EPMC6972567 | biostudies-literature
| S-EPMC4540107 | biostudies-literature
| S-EPMC4324904 | biostudies-literature
| S-EPMC4254688 | biostudies-literature
| S-EPMC3076858 | biostudies-literature
| S-EPMC6148365 | biostudies-literature